AZOPT OPHTHALMIC SUSPENSION 1%

SOLUTION

**4.2 Posology and method of administration** **Posology** When used as monotherapy or adjunctive therapy, the dose is 1 drop of AZOPT eye drops in the conjunctival sac of the affected eye(s) twice daily. Some patients may have a better response with 1 drop 3 times a day. When substituting another ophthalmic antiglaucoma agent with AZOPT eye drops, discontinue the other agent and start the following day with AZOPT eye drops. If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last. Use in elderly No dosage alteration in elderly patients is necessary. Use in children The safety and efficacy of AZOPT eye drops in patients below the age of 18 have not been established and its use is not recommended in these patients. Use in patients with hepatic impairment AZOPT eye drops has not been studied in patients with hepatic impairment, and is therefore not recommended in such patients. Use in patients with renal impairment AZOPT eye drops has not been studied in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2) or in patients with hyperchloraemic acidosis. Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZOPT eye drops is therefore contraindicated in such patients (see also 4.3). However, in patients with moderate renal impairment (creatinine clearance 30–60 mL/min/1.73 m2) there is no need for dose adjustments with topical administration of brinzolamide 1%. **Method of administration** For ocular use. Shake well before use. After cap is removed, if tamper evident snap collar is loose, this should be removed before using the product. To avoid contamination, the dropped tip should not touch any surface. The dropper tip should also not come into contact with the eye as this may cause injury to the eye. Patients should be instructed to keep the bottle tightly closed when not in use. Nasolacrimal occlusion and closing the eyelid for 2 minutes after instillation is recommended. This may result in a decrease in systemic side effects and an increase in local activity. Patients must be instructed to remove soft contact lenses prior to application of Azopt, and to wait 15 minutes after instillation of the dose before reinsertion.